Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
4560
¥ millionWording
Conditional
How definitive the wording is.Results for this period
Third quarter1 April 2025 to 31 December 2025ConsolidatedJapanese GAAPNet Sales54,486¥ millionYear on year +9.1%Progress 76.7%
Operating profit4,911¥ millionYear on year -10.6%Progress 81.9%
Ordinary income4,854¥ millionYear on year -10.9%Progress 80.9%
Net income attributable to owners of the parent3,904¥ millionYear on year -4.7%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share137.59円
Financial position at period-end
Total assets112,699¥ million
of which net assets 74,743 ¥ millionEquity ratio 61.0%vs. prior year-end -1.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenuePharmaceuticals Business ¥45,332 million (YoY +2.9%), Animal Health Business ¥5,759 million (YoY +1.0%), Overseas Business ¥3,240 million, Other ¥153 million (YoY -7.7%)
Segment profitPharmaceuticals Business ¥5,822 million (YoY -6.1%), Animal Health Business ¥368 million (YoY +22.6%), Overseas Business ¥70 million, Other ¥-28 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥71,000 million (YoY +10.7%)
Operating profit¥6,000 million (YoY +12.5%)
Ordinary income¥6,000 million (YoY +17.5%)
Profit attributable to owners of the parent¥5,000 million (YoY -2.0%)
Annual Dividend Forecast¥55 → ¥55（0.0%）
Factors Behind Changes in Business Performance
医療用医薬品事業やアニマルヘルス事業が堅調に推移し、海外事業の売上寄与により売上高が増加した一方、研究開発費等の販管費の増加により営業利益が減少した。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidation0 additions (company name: —), 0 exclusions (company name: —)
Breakdown of extraordinary income (loss)Extraordinary Income ¥96 million
Depreciation and amortization¥2,125 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNone (対象者：Not applicable)
Issued Shares at Period-End28,763,199 Shares
Treasury Shares at Period-End367,074 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025 to 31 December 2025 |
| Net Sales | ¥54,486 million (YoY +9.1%) |
| Operating profit | ¥4,911 million (YoY -10.6%) |
| Ordinary income | ¥4,854 million (YoY -10.9%) |
| Profit attributable to owners of the parent | ¥3,904 million (YoY -4.7%) |
| Net income per share | 137.59円 |
| Equity ratio | End of the current fiscal period 61 / End of previous period 62.6 |
| Total assets | ¥112,699 million |
| Net assets | ¥74,743 million |
| Full-year earnings forecast | Net Sales ¥71,000 million (YoY +10.7%) / Operating profit ¥6,000 million (YoY +12.5%) / Ordinary income ¥6,000 million (YoY +17.5%) / Profit attributable to owners of the parent ¥5,000 million (YoY -2.0%) |
| Annual Dividend Forecast | ¥55 → ¥55（0.0%） |
| Segment revenue | Pharmaceuticals Business ¥45,332 million (YoY +2.9%), Animal Health Business ¥5,759 million (YoY +1.0%), Overseas Business ¥3,240 million, Other ¥153 million (YoY -7.7%) |
| Segment profit | Pharmaceuticals Business ¥5,822 million (YoY -6.1%), Animal Health Business ¥368 million (YoY +22.6%), Overseas Business ¥70 million, Other ¥-28 million |
| Depreciation and amortization | ¥2,125 million |
| Breakdown of extraordinary income (loss) | Extraordinary Income ¥96 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | 0 additions (company name: —), 0 exclusions (company name: —) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 28,763,199 Shares |
| Treasury Shares at Period-End | 367,074 Shares |
| Factors Behind Changes in Business Performance | 医療用医薬品事業やアニマルヘルス事業が堅調に推移し、海外事業の売上寄与により売上高が増加した一方、研究開発費等の販管費の増加により営業利益が減少した。 |
Items this document does not state (12)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.医療用医薬品事業やアニマルヘルス事業が堅調に推移し、海外事業の売上寄与もあったため売上高が増加した。一方、研究開発費等の販管費が増加したため営業利益などは減少した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.